Overview
- The Bureau of Labor Statistics report for July showed prescription drug prices fell 0.8% for the month and 3.1% year‑over‑year, the largest annual decline in the category since 1963.
- The White House says its Most Favored Nation agreements and the TrumpRx discount platform drove the drop and issued a $700 million savings figure that critics say lacks a disclosed methodology.
- Independent health analysts and multiple news outlets attribute the decline to several overlapping causes, including Medicare price negotiations from the 2022 Inflation Reduction Act, new generics and biosimilars entering the market, and falling cash prices for GLP‑1 drugs.
- The CPI measure used by the BLS records what pharmacies receive from insurers and patients at the point of sale and omits manufacturer rebates paid after the sale, so the index may not reflect changes in patients’ out‑of‑pocket costs.
- Observers warn that MFN contracts and implementation details have not been made public, meaning the direct impact of those deals on aggregate prices remains unclear and the political debate will shape scrutiny before midterm elections.